Myung-Hoon Han1, Kyueng-Whan Min2, Yung-Kyun Noh3,4, Jae Min Kim1, Jin Hwan Cheong1, Je Il Ryu1, Yu Deok Won1, Seong-Ho Koh5, Jae Kyung Myung6, Ji Young Park7, Mi Jung Kwon8. 1. Department of Neurosurgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Gyeonggi-do, Republic of Korea. 2. Department of Pathology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Gyeonggi-do, Republic of Korea. kyueng@hanyang.ac.kr. 3. Department of Computer Science, Hanyang University, Seoul, Republic of Korea. nohyung@hanyang.ac.kr. 4. School of Computational Sciences, Korea Institute for Advanced Study, Seoul, Republic of Korea. nohyung@hanyang.ac.kr. 5. Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Gyeonggi-do, Republic of Korea. 6. Department of Pathology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea. 7. Division of Cardiology, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University, Seoul, Republic of Korea. 8. Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Gyeonggi-do, Republic of Korea.
Abstract
BACKGROUND: Glioblastoma multiforme (GBM) is an aggressive malignant primary brain tumor. Wnt/β-catenin is known to be related to GBM stemness. Cancer stem cells induce immunosuppressive and treatment resistance in GBM. We hypothesized that Wnt/β-catenin-related genes with immunosuppression could be related to the prognosis in patients with GBM. METHODS: We obtained the clinicopathological data of 525 patients with GBM from the brain cancer gene database. The fraction of tumor-infiltrating immune cells was evaluated using in silico flow cytometry. Among gene sets of Wnt/β-catenin pathway, Dickkopf-3 (DKK3) gene related to the immunosuppressive response was found using machine learning. We performed gene set enrichment analysis (GSEA), network-based analysis, survival analysis and in vitro drug screening assays based on Dickkopf-3 (DKK3) expression. RESULTS: In analyses of 31 genes related to Wnt/β-catenin signaling, high DKK3 expression was negatively correlated with increased antitumoral immunity, especially CD8 + and CD4 + T cells, in patients with GBM. High DKK3 expression was correlated with poor survival and disease progression in patients with GBM. In pathway-based network analysis, DKK3 was directly linked to the THY1 gene, a tumor suppressor gene. Through in vitro drug screening, we identified navitoclax as an agent with potent activity against GBM cell lines with high DKK3 expression. CONCLUSIONS: These results suggest that high DKK3 expression could be a therapeutic target in GBM. The results of the present study could contribute to the design of future experimental research and drug development programs for GBM.
BACKGROUND: Glioblastoma multiforme (GBM) is an aggressive malignant primary brain tumor. Wnt/β-catenin is known to be related to GBM stemness. Cancer stem cells induce immunosuppressive and treatment resistance in GBM. We hypothesized that Wnt/β-catenin-related genes with immunosuppression could be related to the prognosis in patients with GBM. METHODS: We obtained the clinicopathological data of 525 patients with GBM from the brain cancer gene database. The fraction of tumor-infiltrating immune cells was evaluated using in silico flow cytometry. Among gene sets of Wnt/β-catenin pathway, Dickkopf-3 (DKK3) gene related to the immunosuppressive response was found using machine learning. We performed gene set enrichment analysis (GSEA), network-based analysis, survival analysis and in vitro drug screening assays based on Dickkopf-3 (DKK3) expression. RESULTS: In analyses of 31 genes related to Wnt/β-catenin signaling, high DKK3 expression was negatively correlated with increased antitumoral immunity, especially CD8 + and CD4 + T cells, in patients with GBM. High DKK3 expression was correlated with poor survival and disease progression in patients with GBM. In pathway-based network analysis, DKK3 was directly linked to the THY1 gene, a tumor suppressor gene. Through in vitro drug screening, we identified navitoclax as an agent with potent activity against GBM cell lines with high DKK3 expression. CONCLUSIONS: These results suggest that high DKK3 expression could be a therapeutic target in GBM. The results of the present study could contribute to the design of future experimental research and drug development programs for GBM.
Authors: Menggui Huang; Duo Zhang; Janet Y Wu; Kun Xing; Eujin Yeo; Chunsheng Li; Lin Zhang; Eric Holland; Lutian Yao; Ling Qin; Zev A Binder; Donald M O'Rourke; Steven Brem; Constantinos Koumenis; Yanqing Gong; Yi Fan Journal: Sci Transl Med Date: 2020-02-26 Impact factor: 17.956
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Alex Miranda; Phineas T Hamilton; Allen W Zhang; Swetansu Pattnaik; Etienne Becht; Artur Mezheyeuski; Jarle Bruun; Patrick Micke; Aurélien de Reynies; Brad H Nelson Journal: Proc Natl Acad Sci U S A Date: 2019-04-17 Impact factor: 11.205
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh Journal: Nat Methods Date: 2015-03-30 Impact factor: 28.547
Authors: Ana Laura V Alves; Izabela N F Gomes; Adriana C Carloni; Marcela N Rosa; Luciane S da Silva; Adriane F Evangelista; Rui Manuel Reis; Viviane Aline O Silva Journal: Stem Cell Res Ther Date: 2021-03-24 Impact factor: 6.832
Authors: Xinxin Peng; Zhongyuan Chen; Farshad Farshidfar; Xiaoyan Xu; Philip L Lorenzi; Yumeng Wang; Feixiong Cheng; Lin Tan; Kamalika Mojumdar; Di Du; Zhongqi Ge; Jun Li; George V Thomas; Kivanc Birsoy; Lingxiang Liu; Huiwen Zhang; Zhongming Zhao; Calena Marchand; John N Weinstein; Oliver F Bathe; Han Liang Journal: Cell Rep Date: 2018-04-03 Impact factor: 9.423
Authors: Myung-Hoon Han; Kyueng-Whan Min; Yung-Kyun Noh; Jae Min Kim; Jin Hwan Cheong; Je Il Ryu; Yu Deok Won; Seong-Ho Koh; Young Mi Park Journal: Front Oncol Date: 2022-08-10 Impact factor: 5.738